Biologic drug reduces symptoms, hospitalization for severe pulmonary hypertension after diagnosis

Results of the phase 3 clinical trial suggest benefits for early treatment

2025-09-30

(Press-News.org) Prescribing the biologic drug sotatercept alongside standard treatment for the most severe form of pulmonary hypertension significantly reduces the likelihood of worsening disease when added within the first year after diagnosis, according to a study published in the New England Journal of Medicine.

Within the first year of receiving a pulmonary arterial hypertension (PAH) diagnosis, patients who took sotatercept in addition to standard-of-care therapy reduced the risk experiencing deterioration in health — such as less ability to exercise, worsening symptoms and unplanned hospitalizations — by 76%.

Investigators for the phase 3 clinical trial detected positive results for patients after just three doses of the injectable medication, which sold under the brand name Winrevair.

Results were presented at the 2025 European Respiratory Society Congress in Amsterdam.

“These results are incredibly promising for patients early in their journey with pulmonary arterial hypertension, which still has limited treatment options,” said first author Vallerie V. McLaughlin, M.D., the Kim A. Eagle Endowed Professor of Cardiovascular Medicine at University of Michigan Medical School.

McLaughlin, who directs the Pulmonary Hypertension Program at the U-M Health Frankel Cardiovascular Center, was lead investigator of the double-blind, placebo-controlled HYPERION study.

The clinical trial concluded early due to loss of clinical equipoise, meaning researchers felt they could not ethically continue the study due to overwhelmingly positive results for patients on sotatercept compared to placebo in recent sotatercept randomized, controlled trials.

“PAH is a chronic, progressive condition with high morbidity and mortality, and many patients present at advanced stages of disease,” McLaughlin said.

“Our findings suggest early treatment with sotatercept may help patients to achieve and maintain a lower risk status and improve outcomes.”

Sotatercept is approved by the U.S. Food and Drug Administration for treatment of adults with pulmonary arterial hypertension, or PAH, and is offered in concert with standard-of-care therapies.

The medication offers a novel approach by targeting proteins called activins. In PAH, elevated activin signaling can eventually thicken the pulmonary arteries, putting extra work on the heart to pump blood to the lungs.

Past studies of sotatercept showed benefits for patients with high-risk as well as those with longstanding pulmonary arterial hypertension.

The initial trial, STELLAR, found that patients taking the medication had improved capacity for exercise. The ZENITH trial demonstrated a decreased risk of death, hospitalization and lung transplantation in those at high risk of death.

Patients in both studies had a diagnosis of PAH for an average of seven to eight years. HYPERION extends the evidence base to patients diagnosed within one year.

Fewer than 2% of participants taking sotatercept in the HYPERION trial were hospitalized for worsening PAH symptoms, compared to 8.8% of the placebo group.

The most common adverse events reported with sotatercept were nosebleeds and spider veins.

“The positive effects of adding sotatercept to standard therapy in patients with PAH are remarkable,” said Victor M. Moles, M.D., HYPERION investigator and clinical associate professor of internal medicine-cardiology at U-M Medical School

“The results from the HYPERION trial underscore the critical importance of early intervention, demonstrating that earlier treatment leads to better outcomes.”

Additional authors: For a complete list of HYPERION investigators, view the supplementary appendix.

Funding/disclosures:

This study was funded by Merck Sharp & Dohme, a subsidiary of Merck. The study analyses presented here were funded by Merck Sharp & Dohme, a subsidiary of Merck.

Paper cited: “Sotatercept for Pulmonary Arterial Hypertension within the First Year of Diagnosis,” New England Journal of Medicine. DOI: 10.1056/NEJMoa2508170

END

ELSE PRESS RELEASES FROM THIS DATE:

Experts warn federal cuts may extinguish momentum in tobacco control

2025-09-30

A new commentary paper in Nicotine and Tobacco Research, published by Oxford University Press, argues that recent cuts to the National Institutes of Health, including about $2 billion in terminated research grants and a $783 million cut to research funding linked to diversity and inclusion initiatives, will have a dramatically negative effect on efforts to combat tobacco usage and health disparities in the United States. The health and economic burdens of commercial nicotine and tobacco use are high, contributing to about 480,000 premature US deaths ...

The insomnia trade-off

2025-09-30

One-third of our lives is spent sleeping, yet 30 to 40 percent of adults are reported to experience some form of insomnia. Japan in particular has the lowest sleep duration among the Organization for Economic Co-operation and Development (OECD) countries, falling at one hour below average. Public health research has identified long commutes, noise, and light pollution from densely populated living environments as factors that impair sleep. While such metropolitan housing offers advantages in commuting time, its livability is far less than the suburbs. To find a balance between convenience and sleep, urban architecture research, which examines the relationship between housing location, ...

Natural antimicrobial drugs found in pollen could help us protect bee colonies from infection

2025-09-30

A honeybee hive, with its large stores of pollen, wax, and honey, is like a fortress guarding treasure: with strong defenses, but a bonanza for enemies that can overcome those. More than 30 parasites of honeybees are known, spanning protists, viruses, bacteria, fungi, and arthropods – and this number keeps growing. As a result, beekeepers are always on the lookout for new ways to protect their precious hives. A team of researchers from the US suspected that a rich new source of ecofriendly treatments for bee diseases might be hiding ...

Why mamba snake bites worsen after antivenom

2025-09-30

A breakthrough study at The University of Queensland has discovered a hidden dangerous feature in the Black Mamba one of the most venomous snakes in the world. Professor Bryan Fry from UQ’s School of the Environment said the study revealed the venoms of three species of mamba were far more neurologically complex than previously thought, explaining why antivenoms were sometimes ineffective. “The Black Mamba, Western Green Mamba and Jamesons Mamba snakes aren’t just using one form of chemical weapon, they’re launching a coordinated attack at 2 different points in the nervous system,” Professor Fry said. “If you’re bitten by 3 out of ...

Biogas slurry boosts biochar’s climate benefits by reshaping soil microbes

2025-09-30

Adding biochar to farmland soils is widely promoted as a climate-friendly practice, but its impact on greenhouse gas emissions can vary. A new study finds that pairing biochar with biogas slurry, a nutrient-rich liquid fertilizer from biogas production, can reshape soil microbial communities and significantly alter emissions of carbon dioxide (CO₂), nitrous oxide (N₂O), and methane (CH₄). Researchers from the Chinese Academy of Agricultural Sciences conducted controlled soil column experiments to test how different levels of biochar addition perform ...

New review warns of growing heavy metal threats in reservoirs, calls for smarter monitoring and greener cleanup solutions

2025-09-30

Reservoirs are lifelines for drinking water, food production, and economic growth. But a new study warns that these crucial ecosystems are increasingly under threat from toxic heavy metals—and that urgent, innovative action is needed to safeguard both human health and the environment. Researchers from Northeast Agricultural University, together with international collaborators, have published the most comprehensive review to date of heavy metal pollution in reservoirs, outlining its sources, risks, and promising solutions. The findings, published in Agricultural Ecology and Environment, ...

Positive charges stabilize instantly in key solar fuel catalyst: New simulations track ultrafast polaron formation in NaTaO3.

2025-09-30

summary To boost solar water splitting efficiency, researchers used quantum molecular dynamics to track how charge carriers (polarons) stabilize in the NaTaO3 photocatalyst, a process previously hidden from experiments. They discovered that positive hole polarons stabilize strongly and rapidly (~70 meV in 50 fs) driven by the elongation of oxygen-tantalum (O-Ta) bonds, while electron stabilization is insignificant. This time-resolved, atomistic understanding provides crucial guidelines for rationally engineering O-Ta bond dynamics to create high-performance solar fuel catalysts. Researchers used quantum-chemical molecular dynamics simulations to visualize the ultrafast ...

Tiny but mighty: Groundbreaking study reveals mosses are secret carbon heroes in subtropical forests

2025-09-30

In a lush revelation from the forest floor, a new study published in Carbon Research (as an Open Access Rapid Communication) shows that mosses, those quiet, green carpet-weavers beneath our feet, are climate champions in their own right. Led by Dr. Zhe Wang from the China-Croatia “Belt and Road” Joint Laboratory on Biodiversity and Ecosystem Services, CAS Key Laboratory of Mountain Ecological Restoration and Bioresource Utilization, Chengdu Institute of Biology, Chinese Academy of Sciences, and Shanghai Normal University, alongside Dr. Weikai Bao, also ...

The relaxed birder

2025-09-30

Kyoto, Japan -- Citizen science has allowed regular citizens to participate in data collection as well as expanded biodiversity monitoring. Yet many datasets are still limited to the coverage of certain regions and habitats in particular seasons. In bird research, for example, traditional point‑count surveys often have strict rules regarding the location, timing, and spacing between observation points, making it challenging for citizen volunteers to participate casually. This inspired Masumi Hisano, formerly of Kyoto University and now at Hiroshima University, to try a more flexible approach by conducting counts whenever and wherever possible, as part of his daily routines. As someone ...

Ten-year clinical trial report finds radiation comparable to surgery for early-stage non-small cell lung cancer

2025-09-30

SAN FRANCISCO, September 29, 2025 — A new clinical trial report finds that stereotactic radiation therapy offers long-term survival outcomes comparable to surgery for patients with small, early-stage non-small cell lung cancer (NSCLC). Patients in the study who received radiation also reported fewer side effects after treatment. The STARS trial (NCT02357992) is the first to report ten-year clinical outcomes from a prospective comparison of stereotactic radiation and surgical resection for operable NSCLC. Findings will be presented ...

Measurable residual disease shows strong potential as an early indicator of survival in patients with acute myeloid leukemia

Chemotherapy and radiation are comparable as pre-transplant conditioning for patients with b-acute lymphoblastic leukemia who have no measurable residual disease

Biologic drug reduces symptoms, hospitalization for severe pulmonary hypertension after diagnosis

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: